Background A 38-year-old woman presented with severe headaches to her primary-care physician. The patient had been diagnosed with rheumatoid arthritis and had begun having headache 4 years previously.

Biochemical control cannot be achieved by the use of somatostatin analogs alone in a large number of patients with acromegaly. Combination therapy with somatostatin analogs and the growth-hormone ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, ...

Acromegaly Symptoms. Changes happen slowly, sometimes over years. Your hands and feet are usually large. You might notice a change in your ring or shoe size, especially your shoe width.

Acromegaly is often confused with gigantism, another rare condition that causes excessive growth as a result of high levels ...

A young man’s undiagnosed acromegaly leads to severe cardiac complications, highlighting the genetic links and diagnostic challenges of this rare condition.

This is a report of 22 acromegalic patients — 11 males and 11 females — treated by proton-beam irradiation from May 8, 1963, to April 20, 1967 (44 patients had been treated as of December 31 ...

Symptoms: Symptoms of acromegaly usually begin sometime after puberty, most commonly between the ages of 40 and 50.The disease causes a person's bones to enlarge — most notably, in the hands ...

The medication is a generic form of Sandostatin LAR Depot (Novartis) and is now available for adults in the U.S. with acromegaly or those experiencing severe diarrhea with carcinoid syndrome.

About Oczyesa® (CAM2029)CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide under development for the treatment of three chronic and severe disease indications: acromegaly ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting ...